B
ronchiectasis is a chronic, debilitating respiratory condition that affects people of all ages. It is most prevalent in women and those older than 60 years, and prevalence is increasing. 1 Patients have daily excessive sputum and associated symptoms, recurrent chest infections and impaired health-related quality of life. 2, 3 In North America, management guidelines are lacking. This review discusses best evidence to guide the long-term management of non-cystic fibrosis bronchiectasis in adults, focusing on the two most common single-entity types of bronchiectasis in adults: idiopathic and postinfectious bronchiectasis 4, 5 (Box 1). Table 1 lists all the types of bronchiectasis by cause.
What are the clinical features of bronchiectasis?
First described by Laennec in 1819, bronchiectasis refers to abnormal permanently dilated airways, which are typically described as cylindrical, varicose or cystic in appearance. 10, 11 The condition is characterized by a vicious cycle of persistent bacterial infection and excessive neutrophilic inflammation owing to impairment of airway defence mechanisms. Risk factors for bronchiectasis are related mainly to cause of the disease, with prevalence higher in patients with autoimmune or connective tissue diseases, 5 chronic infections such as HIV 12 and chronic lung disease such as chronic obstructive pulmonary disease 13 and asthma. 14 Both rhinosinusitis and gastroesophageal reflux are also common among patients with bronchiectasis. 5, 15 The typical presenting clinical features are detailed in Box 2.
2, 16 The most common symptom that should prompt suspicion of a diagnosis of bronchiectasis is a persistent cough productive of mucopurulent or purulent sputum. 2, 16 How is bronchiectasis diagnosed?
In patients presenting with clinical features suggestive of bronchiectasis, appropriate baseline investigations include a chest radiograph, lung function tests (forced expiratory volume in the first second [FEV 1 ], forced vital capacity [FVC] , lung volumes and diffusion capacity) and sputum bacteriological culture. 2 These provide useful information for diagnostic triage and surveillance, although they lack specificity and sensitivity to the actual diagnosis of bronchiectasis. 17 
Confirming the diagnosis
The gold standard for confirming the diagnosis is high-resolution computed tomography scan of the chest, ideally done when the patient is clinically stable. 17 Volumetric computed tomography has better sensitivity but may involve greater radiation doses. Typically, thin section (< 1 mm) slices acquired using a highspatial frequency reconstruction algorithm should be used.
18,19

Determining underlying cause
Determination of the underlying cause may alter management in as many as 37% of adults presenting with bronchiectasis. 5 Relevant diagnostic investigations for the most common causes are described in Table 1. tion, perpetuating the vicious cycle of airways infection and inflammation, tissue destruction and presumed disease progression. 22, 23 Chronic infection with certain species has been shown to correlate strongly with clinical features. For example, colonization with Pseudomonas aeruginosa is associated with an increased rate of decline in lung function and poorer health-related quality of life. 24, 25 The most common infecting pathogens are Haemophilus influenzae (47%-55%) and P. aeruginosa (12%-26%), but may also include Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus and other gram-negative pathogens. 21, 26, 27 Less frequently, there may be also be colonization with non tuberculous mycobacteria. 28, 29 Recent research using methods other than standard culture has found evidence of a more diverse bacterial community in the lower airways in bronchiectasis; in one study, more than 140 species were identified in addition to the traditional species listed above. 30 This study also found a significant correlation between such diverse bacterial community and clinical parameters as FEV 1 and patient-perceived cough severity. 30 The clinical application and implication of the results of such alternative diagnostic methods have yet to be fully established.
The natural history of bronchiectasis is variable. Some patients have only a few chest infections per year, with no disease progression over time, while others have more frequent, prolonged infective episodes, and progress more quickly to respiratory failure, with an associated increase in risk of death. Clinical features that may help to identify which patients are at higher risk of disease progression have not yet been formally studied and management continues to focus on limiting further insults to the airways and preserving lung function. Assessing disease severity may aid management decisions. Two validated severity scores are currently used in conjunction with clinical judgment: the FACED score and the Bronchiectasis Severity Index (BSI). 31, 32 The FACED score predicts risk of five-year mortality and is calculated using FEV 1 % predicted, age, chronic Pseudomonas colonization, extent of bronchiectasis (number of affected lobes) and Medical Research Council Dyspnea Scale score. 31 The BSI can be calculated using an online tool (www. bronchiectasisseverity.com). Predictive variables include age, body mass index, FEV 1 % predicted, Medical Research Council Dyspnea Scale score, lobes affected and evidence of chronic bacterial infection. It was initially validated to predict both risk of hospitalization and four-year mortality, but has more recently been found to be useful in predicting other clinical outcomes such as exacerbations, hospitalizations, quality of life, lung function decline and exercise capacity. 33 Outcomes at four years were 0%-5.3% mortality and 0%-9.2% hospitalization for mild score (0-4); 4.0%-11.3% mortality and 9.9%-19.4% hospitalization for moderate score (5-8); 9.9%-29.2% mortality and 41.2%-80.4% hospitalization for severe score (> 9). The utility of either the FACED or BSI score to change with time or respond to intervention has yet to be established. These scores should be used as an adjunct to clinical opinion to inform patient management.
How should bronchiectasis be managed?
The main aims of management are to reduce symptoms, reduce exacerbation frequency and severity, preserve lung function and improve the patient's health -related quality of life.
Education
Several modifiable factors can affect prognosis; therefore, counselling patients regarding lifestyle choices and how they affect the condition is important. Tobacco is a direct insult to the airways and smoking is an independent risk factor for mortality in bronchiectasis; cessation advice should be offered. 34, 35 Nutrition is also important, with lower body mass index an independent risk factor for mortality. 32 An observational cohort study observed vitamin D deficiency to be common in bronchiectasis, as well as associated with worse symptoms and chronic airway infection; individuals may wish to ensure an adequate dietary intake. 36 Exercise training has been proven to provide immediate benefits, with improved exercise capacity, less dyspnea and fewer exacerbations; patients should be encouraged to be active. 37 A deterioration in symptoms suggesting an exacerbation requires early review, and ensuring that both the seasonal influenza and Pneumococcal vaccinations are up to date may reduce the number of exacerbations of bronchiectasis.
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Airway clearance
Clearance of bronchopulmonary secretions is impaired in patients with bronchiectasis. Enhancing effective expectoration of stagnated bronchopulmonary secretions, usually with physiotherapy support, is key to management. Involvement in an exercise training or a pulmonary rehabilitation program has been shown to have beneficial effects. Evidence that supports the usefulness of exercise rehabilitation programs is summarized in Table 2 . 37, [39] [40] [41] [42] The efficacy of regular chest physiotherapy was established in a randomized crossover trial in 2009. 43 Twice-daily physiotherapy improved perceived cough severity by a clinically and statistically significant degree (improvement in Leicester Cough Questionnaire score 1. There are different methods for delivering chest physiotherapy, such as the active cycle of breathing technique, postural drainage, positive expiratory pressure (PEP) and oscillating PEP devices. No single technique has been found to be superior (evidence outlined in Table 3 ), and selection should focus on patient ability and preference so as to optimize compliance. [44] [45] [46] [47] [48] [49] [50] We suggest that all patients should be assessed by a physiotherapist and instructed in chest physiotherapy, with technique and compliance regularly monitored.
Although airway humidification may confer some benefits, current evidence is insufficient for it to be recommended for routine use. A single, small, open-label, randomized, parallel-group, placebo-controlled study that included patients without bronchiectasis found fewer exacerbations (2.97 per patient per year v. Nebulized saline is thought to alter the water concentration of mucus and improve sputum transportability. 52 Currently, there is insufficient evidence to support routine prescription of nebulized saline. One study of eight patients found that nebulized 0.9% (isotonic) saline administered immediately before chest physiotherapy produced more sputum than physiotherapy alone. 53 Other, more recent studies have explored the role of hypertonic saline compared with isotonic (0.9%) saline. A three-month, randomized crossover trial in 32 patients comparing 7% saline and 0.9% saline found that 7% saline significantly improved lung function, as measured by the change in FEV 1 % predicted from baseline at the end of the study with 15.1 (95% confidence interval [CI] 8.2 to 22.0) versus 1.8 (-8.9 to 10.7), p < 0.01. 54 However, a 12-month study in 40 patients comparing 6% saline and 0.9% saline found no clinical superiority of hypertonic saline over isotonic saline, with both groups experiencing an improvement in health-related quality of life and in FEV 1 (by a mean of 90 mL [11 to 169 mL] at 6 mo only. This effect was not sustained at 12 mo). 55 Inhalation of the naturally occurring sugar mannitol is thought to alter the osmotic gradient in the airway lumen, changing the properties of the mucus and enhancing both mucociliary and cough clearance. Despite this rationale, mannitol's role in the longterm management of bronchiectasis is currently unclear. A large, one-year, multicentre, randomized, double-blind trial of twice-daily inhaled mannitol found an increase in time to first exacerbation with treatment (165 d v. 124 d, p = 0.021) and a modest reduction in Purulent, tenacious airway secretions contain excessive quantities of the viscous polymer deoxyribonucleic acid (DNA) released by persistent and uncontrolled neutrophilic activity in the chronically inflamed and infected airways. It has been hypothesized that inhalation of recombinant human deoxyribonuclease (rhDNAse) should cleave the DNA, reducing sputum viscosity and improving expectoration, airway clearance and lung function. However, a randomized, double-blind controlled trial of treatment with rhDNAase for 24 weeks in 349 patients with bronchiectasis found that with treatment, patients had a higher rate of exacerbations, increased use of antibiotics and a greater rate of hospital admissions, as well as a significant reduction in FEV 1 . 57 Inhalation of rhDNAse appears to be harmful and should be avoided by patients with bronchiectasis.
Oral and inhaled N-acetylcysteine (NAC) have not been well studied for bronchiectasis. A meta-analysis of eight randomized controlled trials found some evidence for oral NAC in chronic bronchitis, although not specifically bronchiectasis. 58 Oral NAC is thought to act through its antioxidant properties owing to its low bioavailability in respiratory secretions. Inhaled NAC has not been sufficiently studied in bronchiectasis and neither oral nor inhaled NAC are currently recommended for use.
There is little evidence, and certainly no recent evidence, for other mucolytics in the management of bronchiectasis.
Inhaled corticosteroids and β-agonists
There is insufficient evidence to support routine prescription of inhaled corticosteroids and β-agonists in bronchiectasis without coexisting morbidities such as asthma or chronic obstructive pulmonary disease.
Previous small studies of sputum and bronchial epithelium in patients with bronchiectasis have found fewer inflammatory cells in patients taking regular inhaled corticosteroids. 59, 60 However, there are very few studies exploring the clinical benefit of routine treatment with inhaled steroids. Improvements in reported symptoms and health-related quality of life have been demonstrated, as well as a reduction in sputum volume, in both a randomized, double-blind, placebo-controlled trial 61 and a randomized, double-blind, placebocontrolled crossover trial, 62 but little or no clinical impact has been seen in terms of lung function, exacerbation frequency or sputum bacteriology. The most recent randomized, double-blind parallel study found no impact on lung function or sputum bacteriology in patients with bronchiectasis and airflow obstruction who received a medium-strength inhaled corticosteroid/long-acting β-agonist combination versus a high-dose corticosteroid used in isolation. However, the combined inhaled corticosteroid/long-acting β-agonist provided symptomatic improvement (as measured by the St. George's Respiratory Questionnaire, with a clinical and statistical improvement of -5.3 units in total score, p = 0.006). 63 The use of these agents among patients without comorbidities must consider factors such as presence of airflow obstruction, airway hyperresponsiveness and excessive sputum production, balanced with the risk of adverse effects, such as adrenal suppression. 
Long-term macrolide and antibiotic therapy
Although the antibacterial properties of macrolides were discovered first, these agents have also been shown to have important immunomodulatory effects. It is these immunomodulatory properties -such as inhibition of inflammatory cell chemotaxis, impairment of superoxide generation by activated neutrophils and impairment of mucus hypersecretion -that caused them to be considered as long-term agents in bronchiectasis. Three randomized controlled trials provide evidence to support a trial of longterm macrolide therapy in patients with frequent exacerbations. Their findings are summarized in Table 4 . [65] [66] [67] Although the macrolides were generally well tolerated by patients in these studies, resistance did develop with treatment in the two studies that explored this as an outcome. 65, 66 This may be particularly relevant for patients infected with nontuberculous mycobacteria where macrolides have an important therapeutic role, should the patients require treatment according to current international guidelines for treatment of mycobacterial infection. Cardiovascular events, hepatotoxicity and dysacusis have also been reported with macrolide treatment. The aforementioned trials reported no hepatotoxicity, and a single cardiovascular event (unstable angina), 67 while selfreported auditory problems -occurring in 12% in the treatment arm and 10% in the placebo arm -were reported in one study. 65 Given macrolides' potential adverse effects, patients should be screened before commencing treatment for any evidence of nontuberculous mycobacteria infection, abnormal liver function and electrocardiogram abnormality. Counselling regarding possible hearing loss would be prudent. Further studies are needed to establish the optimum macrolide and regimen to ensure maximum benefit with minimal adverse effects. Macrolide resistance among those who use it for bronchiectasis needs further study.
Long-term antibiotic treatment offers a reasonable therapeutic option; the rationale is that reducing the bacterial burden and improving airway inflammation may promote healing of the bronchial tree, limiting symptoms and leading to fewer exacerbations, improved mortality and better health-related quality of life. Despite this, there have been few studies of long-term anti biotics in bronchiectasis and no inhaled or oral antibiotic agents are currently licensed for long-term use in bronchiectasis in North America. In an attempt to address this urgent need for evidence-guided treatment, the last six years have seen several important new trials exploring the role of long-term antibiotics for this indication. These studies have all focused on inhaled antibiotics, offering targeted drug delivery with minimal systemic adverse effects, but with a risk of bronchospasm and increased expense. [68] [69] [70] [71] [72] This evidence is summarized in Table 5 . Overall, these studies provide support for the role of long-term antibiotics in patients with bronchiectasis and chronic infectionparticularly those infected with P. aeruginosa -although more evidence is needed, particularly given the heterogeneous nature of bronchiectasis and the strict patient inclusion criteria in the trials published to date. Consideration of antibiotic choice should take into account tolerability (with a challenge dose measuring pre-and postdrug FEV 1 mandatory for all patients), colonizing pathogen and cost. Antimicrobial stewardship is important and the patient's culture and mycobacterial status should be reviewed, airway clearance management optimized and other associated comorbidities (such as reflux or rhinosinusitis) addressed before long-term antibiotics are considered. We suggest that those commenced on long-term antibiotics should be reviewed regularly (every six months) with assessment of clinical efficacy, toxicity and sputum cultures regarding ongoing need.
Management of comorbidities
Anxiety and depression are frequent among patients with bronchiectasis, with studies finding evidence of depression in 21.1% to 34% and anxiety in 39.8% to 55% of patients. 73, 74 Frequent review of patients' mental state is warranted, along with appropriate referral for management of clinically distressing mental illness. Recent evidence has suggested an increased risk of cardiovascular disease in patients with bronchiectasis; review of other modifiable cardiovascular disease risk factors and their appropriate management is important. 75, 76 Other comorbidities -such as gastroesophageal reflux, postnasal drip, asthma and chronic obstructive pulmonary disease -complicate bronchiectasis and their management should be optimized.
Surgery and transplant
Surgery is reserved predominantly for localized disease that is refractory to medical management and causing substantial morbidity, such as recurrent or life-threatening hemoptysis. Reported outcomes from retrospective surgical case reviews are good, with a study of 75 patients with a median 15.3-month follow-up from surgery finding 84% asymptomatic and 10.7% describing substantial clinical improvement; 77 a separate study of 277 patients found 68.5% were symptom free at 4.5 years from surgery. 78 Patients with bronchiectasis and advanced lung disease despite compliance with maximal medical management should be considered for referral for transplant. Current transplant guidelines suggest that an FEV 1 ≤ 30% predicted (given the associated high oneyear mortality risk) or an FEV 1 > 30% predicted but with rapid decline, frequent hospital admissions, worsening cachexia or massive hemoptysis, resting hypoxemia and hypercapnia are all indicators for a referral to the transplant clinic. 79 A recent retrospective review of 34 patients who received transplants (33 double-lung and 1 single-lung) for bronchiectasis between 1992 and 2014 found a one-year survival of 85% and five-year survival of 73%. 80 
Conclusion
Accumulating and increasingly robust evidence now supports the management of adults with bronchiectasis. However, many questions remain unanswered (see Box 3) and further, larger, consistently well-designed studies are needed in order to continue to advance our knowledge and understanding of bronchiectasis as well as treatment of the disease.
